Nisa Investment Advisors LLC Purchases 247 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% ...
precisionmedicineonline21h
Roche Looks Forward to Itovebi Approval in Europe Amid Steady Q4 Revenue Growth
The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.
Factbox-Wall St gears up for fallout from likely tariffs on Canada and Mexico
Global policymakers and Wall Street analysts have been bracing for massive trade barriers from the new Trump administration.
From special rewards to travel perks, here are the best credit card offers of February 2025
My vote for the best credit card offer of February 2025 goes to my favorite hotel card: the IHG One Rewards Premier Credit ...
JD Supra23h
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...
Muscular Dystrophy News2h
To a parent, the years always seem too short
Columnist Betty Vertin has learned that as a parent, she's finding the years with all her children, including those with DMD, too short.
MarketWatch22h
Sarepta Therapeutics Inc.
Dyne Therapeutics Inc.-3.02% $1.48B ...